AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, released news earlier this morning on a planned interim analysis of its ongoing ANDES Phase 3 clinical trial of AGI-1067 for the treatment of Type 2 diabetes. The on-going study of 806 patients who completed three months in the study showed dose-related, statistically significant reductions in A1c. Final results are expected later on this year.

“The ANDES trial is ongoing and we must await final data before drawing firm conclusions,” commented Alexander Fleming, M.D., acting Chief Medical Officer. “We are encouraged by these early results, which show a meaningful reduction in blood sugar for patients with diabetes taking AGI-1067. The interim data also suggest that this three month assessment may not be capturing the full effect of AGI-1067 on A1c reduction, which is the standard clinical measure of blood sugar control.”

AtheroGenics is primarily focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease. The company is also working on an oral drug to help prevent organ rejection.

Let us hear your thoughts below: